Sibylla Biotech Appoints Usman Azam CEO, Gianluca Fuggetta CFO, and Expands Executive Team to Drive Transition to Clinic
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson's Disease and Movement Disorders
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson's Disease
Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update
QIMC Extends DDH-26-05 Drilling to Beyond 1,000 Metres and Launches In-Situ Hydrogen Characterization and Extraction Program at Bennett Hill as Seismic Further Corroborates Two Distinct Hydrogen Systems in Nova Scotia
